Maricann Group (CNSX:MARI – Get Free Report) had its target price hoisted by stock analysts at Raymond James from $6.00 to $6.50 in a research note issued to investors on Tuesday, BayStreet.CA reports.
Separately, Canaccord Genuity Group reduced their target price on shares of Maricann Group from $6.50 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday, January 12th.
View Our Latest Analysis on Maricann Group
Maricann Group Stock Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Recommended Stories
- Five stocks we like better than Maricann Group
- Stock Dividend Cuts Happen Are You Ready?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
